An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

Hasanov, M., Milton, D. R., Sharfman, W. H., Taback, B., Cranmer, L. D., Daniels, G. A., Flaherty, L., Hallmeyer, S., Milhem, M., Feun, L., Hauke, R., Doolittle, G., Gregory, N., & Patel, S. (2021). An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.1984059
Authors:
Merve Hasanov
Denái R Milton
William H Sharfman
Bret Taback
Lee D Cranmer
Gregory A Daniels
Lawrence Flaherty
Sigrun Hallmeyer
Mohammed Milhem
Lynn Feun
Ralph Hauke
Gary Doolittle
Nancy Gregory
Sapna Patel
Affiliated Authors:
Bret Taback
Columbia Affiliation:
Subjects:
Interleukin-2 (MeSH)
Melanoma (MeSH)
Author Keywords:
clinical trial
high dose interleukin-2
ipilimumab
metastatic melanoma
elink
Publication Type:
Article
Unique ID:
10.1080/2162402x.2021.1984059
PMID:
34650833
DOI:
10.1080/2162402x.2021.1984059
Journal:
OncoImmunology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: